# US 2014/0194360 A1 · Use of antithrombin in extracorporeal membrane oxygenation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194360 A1
- Document ID: US20140194360A1
- Status: Published application
- Kind: A1
- Application number: 14/239,943
- Filed: 2013-08-02
- Published: 2014-07-10
- Earliest claimed: 2012-08-03
- Assignees: rEVO Biologics, Inc.
- Inventors: Johan Frieling; Simon Lowry
- Web page: https://patentgrep.com/patent/US20140194360A1

## CPC

- A61K 31/727: Heparin; Heparan
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one aspect, the disclosure provides methods of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®.

## Claims

### Claim 1

A method of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation, the method comprising:
administering to a subject having extracorporeal membrane oxygenation a therapeutically effective amount of antithrombin to suppress blood clotting and/or prevent hemorrhage.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antithrombin has a high mannose glycosylation pattern.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the antithrombin has a high fucose glycosylation pattern.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the antithrombin comprises GalNac (N-acetylgalactosamine).

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the antithrombin is transgenically produced antithrombin.

### Claim 6 (depends on 5)

The method of claim 5, wherein the antithrombin is transgenically produced in a goat.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the antithrombin is ATryn®.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the antithrombin is administered at a dose of 6 units per kg.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the antithrombin is administered at a dose of 80 units per kg.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the antithrombin is administered at a dose of 295 units per kg.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the antithrombin is administered at a dose sufficient to maintain a level of antithrombin activity present in the blood at the time of initiation of extracorporeal membrane oxygenation.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the antithrombin is administered in one dose.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the antithrombin is administered by a bolus followed by continuous infusion.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, further comprising administering heparin.